During a virtual live event with other physicians, Sandy Srinivas, MD, reviewed data for 3 antiandrogens used for patients with nonmetastatic castration-resistant prostate cancer, including apalutamide, darolutamide, and enzalutamide.
Androgen Receptor Inhibition in CRPC
In a roundtable discussion with multiple participants, Alicia K. Morgans, MD, MPH, discusses PSA doubling time and participant experience with androgen receptor inhibitors in castration-resistant prostate cancer.
In a roundtable discussion with multiple participants, Alicia K. Morgans, MD, MPH, reviews the options for a patient with castration-resistant prostate cancer who progressed on front-line therapy.
In a roundtable discussion with multiple participants, Alicia K. Morgans, MD, MPH, covers prostate-specific membrane antigen and Axumin testing in castration-resistant prostate cancer.
In a roundtable discussion with multiple participants, Alicia K. Morgans, MD, MPH, leads a conversation on germline testing and molecular imaging in castration-resistant prostate cancer.